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Amiodarone is a widely used anti-arrhythmic drug with
considerable potential to cause thyroid dysfunction (TD)
because of its 35% iodine content.1 Indeed, each 200 mg tablet
(the usual daily maintenance dose) contains 75 mg of organic
iodide with approximately 7.5 mg free iodide being released
daily. This greatly exceeds the daily dietary iodine requirement
of 0.2 - 0.8 mg.2
The frequency of reported TD with amiodarone therapy has
ranged from 2% to 24%.3 It is generally accepted that the
frequency of hypothyroidism and hyperthyroidism is
accounted for by differing levels of iodine intake.
Hyperthyroidism is therefore most likely to occur in patients
from areas with low environmental iodine in contrast to
hypothyroidism where patients hail from iodine-replete or
excess areas. The mechanism of amiodarone-induced
hypothyroidism may be mediated by excess iodide. The large
amount of iodide released by metabolism of amiodarone
inhibits thyroid hormone biosynthesis (the Wolff-Chaikoff
effect).  Escape from the Wolff-Chaikoff effect usually occurs,
yet there is persistence of the hypothyroid state in patients
with amiodarone-induced hypothyroidism. This is attributed to
a subtle defect in thyroid hormonogenesis that results in
enhanced susceptibility to the inhibitory effect of iodine on
hormone synthesis.4,5 A disturbance of intrinsic thyroid iodine
autoregulation is thought to account for amiodarone-induced
thyrotoxicosis, but these mechanisms are incompletely
understood.2,4,6,7
Hyperthyroid states associated with amiodarone have
traditionally been categorised into two main classes.  Type 1
refers to patients with an underlying thyroid disorder such as
multinodular disease or Graves’ disease, who on exposure to
an excessive amount of iodine develop thyrotoxicosis.  Type 2
hyperthyroidism is characterised by an absence of either
Graves’ disease or multinodular disease, but the thyroid is
vulnerable to inflammatory attack.8,9
In addition to the abovementioned forms of TD, amiodarone
may also induce minor derangements of thyroid function tests.
These are not clinically significant, should be recognised as the
effect of amiodarone, and do not require any specific therapy.
Amiodarone is a potent inhibitor of type 1 and type 2 
5’-deiodinase of thyroxine, the enzymes that convert T4 to T3.
This inhibition may result in an elevated thyroid-stimulating
hormone (TSH) level, together with a mildly elevated or
normal T4 and a low T3 level.10 In addition, amiodarone affects
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Background.  Little is known about the frequency of thyroid
dysfunction (TD) associated with amiodarone therapy in
southern Africa.
Objectives.  To determine the incidence of TD in a cohort of
patients initiated on amiodarone therapy at a cardiac clinic in
Cape Town, South Africa, believed to be an iodine-replete
area.
Patients.  Pharmacy records were used to obtain the names of
patients who received amiodarone between November 1999
and December 2002.
Results.  The sample size was 194, but data analysis was
limited to the 163 patients for whom there were complete
data. The mean age ± standard deviation (SD) was 59.0 ± 15.0
years (range 22 - 89 years). There were 67 female and 96 male
patients.  The indications for amiodarone therapy were
supraventricular tachycardias (N = 102, 62.6%), ventricular
tachycardia (N = 55, 33.7%), and prophylaxis against
tachycardias (N = 3, 1.8%).  The indication was uncertain in 3
patients (1.8%).  The median duration of amiodarone
treatment was 679.0 days (quartile deviation (QD) 1 172 days,
range 3 - 6 425 days) in the whole cohort. The median
duration of amiodarone therapy until new TD was 943 days
(QD 1 185 days), significantly longer than in patients who
remained euthyroid (547 days, QD 1 135 days) (P = 0.05).
There were 45 new TD cases (27.6%): 11 patients (6.7%) were
thyrotoxic, 1(0.6%) transient thyrotoxicosis, 1 (0.6%)
subclinical hyperthyroidism, 13 (8.0%) had subclinical
hypothyroidism, 12 (7.4%) hypothyroidism and 7 (4.3%) had
minor changes in thyroid function.
Conclusions.  We found a high incidence of new-onset TD,
similar to the highest rates reported internationally.  Local
factors responsible for this need to be investigated.
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pituitary release of TSH and may therefore cause the
inappropriate TSH syndrome.3,4,10
Little is known about the frequency of TD related to
amiodarone use in southern Africa, as the reported studies
emanate from Europe and the USA.  We therefore examined
the incidence of TD in a cohort of patients started on
amiodarone therapy at the cardiac clinic, Groote Schuur
Hospital in Cape Town.  Groote Schuur Hospital is the
teaching hospital of the University of Cape Town and is a
referral centre for patients with cardiac arrythmias resident in
Cape Town and surrounding areas.  As Cape Town is believed
to be an iodine-replete area, it was assumed that
hypothyroidism would be the most common form of TD
associated with amiodarone use.5,11,12
Materials and methods
The names of all patients who received amiodarone between
November 1999 and December 2002 were obtained from the
hospital pharmacy records. Only patients with either cardiac
notes or hospital folders were included in the study.
Demographic and medical details were extracted from the
notes. The medical data included the indication for amiodarone
therapy and results of thyroid function tests. TD was
categorised by two board-certified specialist endocrinologists
(Table I). The serum samples for TSH, fT4 and fT3 were
measured using the automated chemiluminescence assays
manufactured by Bayer Corporation, New York, USA. The
interassay co-efficient of variation for TSH was 5.48%, for  fT4
4.6%, and for fT3 2.3%.  All thyroid function tests were assessed
at baseline and at 3 - 6 monthly intervals.
The statistical analyses were performed using Student’s t-
test. All values were expressed using either the mean ±
standard deviation (SD) or median ± quartile deviation (QD),
except when noted.  p-values ≤ 0.05 were considered
statistically significant.
Results
One hundred and ninety-four patients received amiodarone
during the study period, but the analysis was limited to 163
patients for whom the data were complete.  The 31 participants
with incomplete data did not differ statistically from the
remaining subjects in terms of gender and age, but the median
duration of exposure to amiodarone was 219 days in the
former versus 1 008 days in the cohort with complete data
(p < 0.01).  The study participants were 59 ± 15 years of age.
There were 67 women and 96 men. TD antedating amiodarone
therapy was present in 13 patients (8%). The indications for
amiodarone therapy are shown in Table II.
New-onset TD occurred in 45 patients (27.6%).  Eleven
patients (6.7%) were thyrotoxic, 1 (0.6%) had transient
thyrotoxicosis, 1 (0.6%) subclinical hyperthyroidism, 13 (8.0%)
had subclinical hypothyroidism, 12 (7.4%) hypothyroidism and
7 (4.3%) developed minor changes in thyroid function.  Seven
of the patients with hypothyroidism and 1 with subclinical
hypothyroidism were managed with thyroxine.  The
cardiologists adopted a protocol whereby they chose to
manage hypothyroidism secondary to amiodarone in the
following way:  if the patients were found to be hypothyroid,
the need for amiodarone was reviewed. If an arrhythmia
necessitated continued use, thyroxine was added.  If
amiodarone could be stopped the thyroid function tests were
reviewed 3-monthly.  Thyroxine was introduced if the
hypothyroidism persisted beyond 3 months.  Subclinical
hypothyroid cases were observed for the evolution of
hypothyroidism.
Amiodarone was stopped in 6 of the 12 patients with
thyrotoxicosis.  One patient with subclinical hyperthyroidism
was managed with a reduced dose of amiodarone.  Therapy for
the thyrotoxic patients consisted of amiodarone withdrawal
where the cardiovascular status permitted this, radioactive
iodine if a sufficient period had elapsed since the withdrawal
of amiodarone to permit adequate iodine uptake by the thyroid
gland, and neomercazole or prednisone or a combination of
Table I. Thyroid diagnoses by thyroid function testing
Diagnosis Definition
Euthyroidism TSH 3.5 - 5.5 µIU/ml
fT4 11.5 - 22.7 pmol/l
fT3 3.5 - 6.5 pmol/l
Thyrotoxicosis TSH < 0.01 µIU/ml
fT4 > 22.7 pmol/l
fT3 > 6.5 pmol/l
Subclinical hypothyroidism TSH >5.5 µIU/ml
fT4 11.5 - 22.7 pmol/l
fT3 3.5 - 6.5 pmol/l
Hypothyroidism TSH > 5.5 µIU/ml
fT4 < 11.5 pmol/l
fT3 < 3.5 pmol/l
Minor changes in thyroid function TSH > 5.5 µIU/ml
fT4 11.5 - 22.7 pmol/l or
fT3 ≥ 3.5 pmol/l
Subclinicial hyperthyroidism TSH < 0.01 µIU/ml
fT4 11.5 - 22.7 pmol/l
fT3 3.5 - 6.5 pmol/l
f = free.
Table II. Indications for amiodarone therapy
Indications Number of patients (%)
Supraventricular tachycardia 102 (62.2)
Ventricular tachycardia 55 (33.7)
Prophylaxis against tachycardia 3 (1.8)
Uncertain 3 (1.8)
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both neomercazole and prednisone.  The treatment of
amiodarone-induced thyrotoxicosis was not uniform as
different attending physicians offered a variety of expert
opinions.
Mortality for the cohort of 163 patients was 12.6%
(confidence interval (CI) 7.9 - 18.8%).  There was no association
between mortality and TD (r = 0.04, p > 0.8).  The median
duration of amiodarone treatment was 679.0 days (range 3 - 
6 425).  Three-quarters of the cohort received amiodarone for
less than 1 172 days.  As seen in Table III, the subjects with
new-onset thyroid dysfunction had significantly longer
duration of amiodarone therapy than those who remained
euthyroid (p = 0.05).  In a life-table analysis, using a Kaplan-
Meier curve, it was shown that the first 1 000 days represented
the period in which patients were most likely to develop TD.
Thereafter the likelihood of developing TD plateaued (Fig. 1).
Discussion
This report represents one of the largest retrospective analyses
of TD associated with amiodarone therapy, with a higher
frequency of TD demonstrated than in previous studies.13
Environmental iodine content has had a major impact on the
distribution of the various forms of thyroid dysfunction.
Therefore, in other settings in which iodine is replete,
hypothyroidism has been the most common abnormality,
ranging from 1% to 32%.4,11 Hypothyroidism was the most
common TD in our study, conducted in the iodine-replete Cape
Town area, yet it still constituted a much smaller proportion of
TD than in previous studies.4,13 The reason for this observation
is unclear.  In many parts of the world TD is not uncommon in
people over the age of 60 years.  We have previously found
that 11.2% of residents in old-age homes in Cape Town had
some degree of TD.14 This is similar to the prevalence of TD
antedating the initiation of amiodarone therapy in the current
cohort.  As the patients in this study were not examined for an
underlying cause of TD, it was attributed to amiodarone.  It is
conceivable, however, that new thyroid dysfunction related to
amiodarone use may have been overestimated.
The total thyrotoxicosis prevalence was 7.3% in our study,
compared with previous reports of 1 - 23%.3,8 Amiodarone-
induced thyrotoxicosis prevails in areas with low iodine intake;
therefore thyrotoxicosis is more common among Italian than
American patients (10% compared with 2%), but
hypothyroidism is less common (2% compared with 22%).4,11
Despite the normal environmental iodine exposure in Cape
Town, we found a relatively high incidence of
hyperthyroidism.  It is therefore plausible that a factor other
than iodine exposure may be responsible for the wide variation
in frequency of TD.  In this retrospective study it was not
possible to determine whether the thyrotoxicosis in our
patients was as a result of type 1 or type 2 amiodarone-induced
thyrotoxicosis or a combination of both.  These patients were
not investigated and managed according to a specific protocol
as none was in place in our hospital.
Management of amiodarone-induced thyrotoxicosis is
difficult and withdrawal of amiodarone may not be possible,
particularly when used for treatment of ventricular
arrhythmias. Moreover even if withdrawal is permitted,
thyrotoxicosis may take as long as 8 months to subside by
virtue of the prolonged half-life of amiodarone.4 Amiodarone-
induced thyrotoxicosis often responds to antithyroid drugs.
Prednisone has proved beneficial in some circumstances,
especially in type 2 amiodarone-induced thyrotoxicosis.4,8
Thyroidectomy is reserved for intractable thyrotoxicosis
unresposive to medical therapy.  However, none of our patients
required this intervention.  There are a number of options for
treating amiodarone-induced hypothyroidism.  These include
discontinuing amiodarone therapy, decreasing the dose, or
Table III. Clinical characteristics of new-onset thyroid dysfunction
versus euthyroidism in patients treated with amiodarone
New thyroid
dysfunction Euthyroidism
(N = 45) (N = 105) 
Clinical characteristics
Age (yrs) (mean ± SD) 60 ± 15.2 57.7 ± 15.3 
Gender (%) Males 66.7 Males 58.1 
Duration of treatment 
(median (QD)) days 943 (QD = 1 185) 547 (QD = 1 135)*
Mortality (%) 13.9 16.4 
Indications for 
treatment (%)
Supraventricular 
tachycardias 51 68.6†
Ventricular tachycardia 44 28.6†
Prophylaxis 0.0 1.9 
Uncertain 4.4 1.0
* p = 0.05.
† p = 0.04.
Fig. 1. Kaplan-Meier curve of cumulative risk for development of
thyroid dysfunction.
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administering replacement therapy with thyroxine.4,5,9
Previous life-table analysis has indicated that 49% of patients
receiving amiodarone develop TD by 36 months of follow-up.3
We have shown that the first 1 000 days represents the most
likely period in which patients will develop thyroid
dysfunction.  Nevertheless, the longer an individual is exposed
to amiodarone the higher the likelihood of developing TD.
This suggests that amiodarone-induced TD is the result of
prolonged exposure, warranting continued surveillance of
thyroid function in patients on amiodarone therapy.
Our study has some limitations. Although it represents one
of the largest data collections, the analysis was restricted to 163
patients (84% of the total) with complete data. Demographic
characteristics of the 31 patients excluded from data analysis
did not differ from those of the remaining patients.  However
those with incomplete data had a shorter exposure to
amiodarone, possibly because of the omission of thyroid
function testing in patients given a short course of therapy.
This may have introduced a degree of bias.  In common with
other retrospective analyses, clinical data were often deficient
and therefore the clinical assessment of goitre size and testing
for thyroid antibodies were not performed routinely.  We
suggest that the following be undertaken before initiating
amiodarone therapy: clinical examination of the thyroid gland
and examination for features of Graves’ disease, and exclusion
of thyroid-associated ophthalmopathy.  Thyroid function tests
and thyroid antibody screening should be requested at
baseline.  This will help to identify patients at increased risk of
TD. Measurements of TSH, fT4 and fT3 should therefore be
reassessed 3 months after commencing amioadarone.
Thereafter TSH should be checked every 4 - 6 months.  An
elevated TSH, together with a low fT4, indicates
hypothyroidism and necessitates treatment with thyroxine.  An
abnormally low TSH, or a drop in TSH, requires assessment of
fT3 and fT4.  A suppressed TSH with both an elevated fT4 and
fT3 confirms hyperthyroidism and necessitates investigation
and treatment.4
Conclusion 
In conclusion, we found an overall high incidence of
amiodarone-induced TD in the Western Cape.  Local and
environmental factors that may explain this high incidence
require investigation.  Ideally amiodarone-induced TD should
be managed jointly by endocrinologists and cardiologists using
an evidence-based protocol.
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